AN2 Therapeutics (ANTX) vs Emmis Acquisition (EMIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics is the larger company by market cap ($169.6 million vs $162.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | EMIS |
|---|---|---|
| Share price | $4.50 | $10.27 |
| Market cap | $169.62M | $162.02M |
| 1-day change | -3.95% | 0.00% |
| YTD return | +310.53% | +3.22% |
| 1-year return | +262.79% | — |
| EPS (TTM) | $-1.05 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $10.27 |
| 52-week low | $1.00 | $9.90 |
| Distance from 52-week high | -37.48% | 0.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +100.22% | — |
| Average volume | 240.21K | 13.67K |
| Shares outstanding | 37.74M | 11.94M |
| Employees | 21 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
ANTX vs EMIS FAQ
Which is bigger, AN2 Therapeutics or Emmis Acquisition?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $169.62M compared with $162.02M for Emmis Acquisition (EMIS).
Are AN2 Therapeutics and Emmis Acquisition in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.